a leader in artificial intelligence (AI) for early, efficient detection of lung nodules, announce the growth of its relationships across the lung imaging ecosystem at the 107th Annual Radiological Society of North America (RSNA) meeting, November 28-December 2, 2021 (South Hall #4129).
Riverain’s partnerships with OEMs, AI vendors, PACS providers, and reporting and patient management companies have grown in depth and breadth, providing customers with a more seamless enterprise-wide access to earlier, more efficient detection of lung abnormalities.
“Riverain tech was proud to introduce the first FDA approved chest algorithm almost 10 years ago and we are dedicated to continuously enhance our technology to improve clinical accuracy and efficiency,” said Steve Worrell, CEO. “At the same time, by expanding partnerships with key players across the ecosystem, we continue to deliver on an important promise to our users: your acquisition, your workflow, your peace-of-mind.”
Riverain will highlight its many strategic partnerships complementing the ClearRead suite of applications, providing enhanced end-to-end lung imaging and cancer screening capabilities:
Acquisition: expanded partnerships with multiple OEMs as well as other AI vendors to ensure the most complete and clinically relevant solutions possible. New partnerships include Aidoc, Imbio, and Volpara Health
Reading: enhanced collaboration with PACS vendors such as Nuance and Sectra to ensure a workflow so seamless that it’s almost invisible
IT integration: working with AI orchestrators to ensure easy access to functionality at every institution and in a purchasing/IT friendly manner
Care Coordination: developing relationships with and creating workflow enhancements to patient management and care coordination tools to ensure that patients who are found to have issues are followed and managed effectively.
ClearRead applications are approved for concurrent reading, saving radiologists time and steps in enhanced image review. The ClearRead suite significantly improves a clinician’s ability to accurately and efficiently detect disease using patented vessel (CT) and bone (X-ray) suppression technology in thoracic images—for earlier, more efficient detection of lung abnormalities. For more information or to schedule an appointment.